Wegovy, popular weight-loss drug, launches in China

Weight-loss treatment reaches 180M in China (Wegovy in Picture)

Novo Nordisk has introduced its weight-loss drug Wegovy in China following its approval by local health authorities in June. The launch sets the stage for increased competition with Eli Lilly, whose weight-loss treatment has also been approved but is not yet available in China's pharmaceutical market, the second-largest globally.

China, with a population of 1.4 billion, has over 180 million people living with obesity. Wegovy, priced at 1,400 yuan (approximately $194 or £153) for four injections, is significantly cheaper in China than in the United States, where a month's supply costs $1,349. However, Chinese patients must pay out-of-pocket as the drug is not covered by national healthcare insurance.

Wegovy’s active ingredient, semaglutide, suppresses appetite and helps control blood sugar, aiding patients in losing over 10% of their body weight. However, potential side effects, such as nausea and vomiting, and weight regain after stopping treatment remain concerns.

Novo Nordisk highlighted on WeChat that Wegovy offers a safe and effective option for addressing obesity in China. Globally, the drug’s success, fueled by celebrity endorsements and social media buzz, has made Novo Nordisk Europe’s most valuable company, with a market value exceeding $440 billion. However, regulatory agencies like the UK's MHRA have warned against misuse by individuals who are not obese, noting reports of adverse effects in such cases.